Bezafibrate as differentiating factor of human myeloid leukemia cells

Cell Death and Differentiation

Volumn 6, Issue 8, 1999, Pages 781-787

  Scatena, R ^a,b   Nocca, G ^a   De Sole, P ^a   Rumi, C ^a   Puggioni, P ^a   Remiddi, F ^a   Bottoni, P ^a   Ficarra, S ^c   Giardina, B ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NONE

Author keywords

Bezafibrate; Cancer; Clofibric acid; Differentiation; Gemfibiozil; Oxidative stress; Reactive oxygen species (ROS)

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; MITOSIS; MYELOID LEUKEMIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032851536     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400551     Document Type: Article

References (17)

1. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-649
2. Chance DS, McIntosh MK (1995) Hypolipidemic agents alter hepatic mitochondrial respiration in vitro. Comp. Biochem. Physiol. 111C: 317-323
3. Perutz MF, Poyart C (1983) Benzafibrate lowers oxygen affinity of hemoglobin. Lancet 2: 881-882
4. Scatena R, Nocca G, Messana I, De Sole P, Baroni S, Zuppi C, Castagnola M, Giardina B (1995) Effects of gemfibrozil on the oxygen transport properties of erythrocytes. Br. J. Clin. Pharm. 39: 322-327
5. Harper S (1989) Myotonic dystrophy II, W.B. Saunders, London.
6. Youssef J, Badr M (1998) Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit. Rev. Toxicol. 28: 1-33
7. Marks PA, Rifkind RA (1991) Differentiating factors. In Biologic Therapy of Cancer. De Vita V.T., Hellman S., Rosenberg S.A. Eds. (J.B. Lippincott Company, Philadelphia) pp. 754-762
8. Scott SE (1997) Differentiation, differentiation/gene therapy and cancer. Pharmacol Ter 73: 51-65
9. Brown MS, Goldstein JL (1990) Drugs used in the treatment of hyperlipoproteinemias. In The Pharmacological Basis of Therapeutics, Eighth Edition, eds Gilmann AG, Rall TW, Nies AS, (New York: Pergamon Press) pp. 874-896.
10. Skehan P (1995) Assay of cell growth and citoxicity. In Cell Growth and Apoptosis. Studzinski GP Eds (IRL Press, Oxford).
11. Ramachandra S, Studzinski P (1995) Morphological and biochemical criteria of apoptosis. In Cell Growth and Apoptosis. Studzinski GP Eds (IRL Press, Oxford) pp 119-142
12. Crissman HA (1995) Cell cycle analysis by flow cytometry. In Cell Growth and Apoptosis. Studzinski GP Eds. (IRL Press, Oxford) pp 65-78
13. De Baetselier P, Scrham E (1986) Luminescent bioassay based on macrophage cell lines. Methods Enzymol. 133: 507-530
14. Allen RC (1986) Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133: 449-492
15. Rowley PT, Ohlsson-Wilhelm BM, Farley BA, La Belle S (1981) Inducers of erythroid differentiation in K562 human leukemia cells. Exp. Hemat. 9: 32-38
16. Moretta L, Pende D, Varese P (1989) Marcatori linfocitari. In Immunologia e immunopatologia. Romagnani S, Moretta L Eds (USES, Firenze) pp 169-190
17. L. Cancer Res. 56: 1621-1628